Automate Your Wheel Strategy on NXTC
With Tiblio's Option Bot, you can configure your own wheel strategy including NXTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NXTC
- Rev/Share 0.0
- Book/Share 1.9943
- PB 0.2467
- Debt/Equity 0.088
- CurrentRatio 10.2608
- ROIC -0.8643
- MktCap 13800698.0
- FreeCF/Share -1.4864
- PFCF -0.3315
- PE -0.2782
- Debt/Assets 0.0732
- DivYield 0
- ROE -0.7016
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NXTC
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.
Read More
About NextCure, Inc. (NXTC)
- IPO Date 2019-05-09
- Website https://www.nextcure.com
- Industry Biotechnology
- CEO Mr. Michael S. Richman MSBA
- Employees 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.